

NRG Oncology Presentation Schedule
Oral and Poster Presentations
SAN FRANCISCO, CA JANUARY 19-21, 2023

Disease Site & Study #	Friday, January 20, 2023	Time*/Location
GI-Non-Colorectal NRG/TOG 1112	Title: <i>NRG/RTOG 1112: randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC) (NCT01730937)</i> Presenter: Laura A Dawson, MD Abstract #: 489	Session Time: 4:30-6:00 PM Location: Level 3, Ballroom Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract Time: 4:40-4:50 PM Oral Presentation
Disease Site & Study #	Saturday, January 21, 2023	Time*/Location
GI-Colorectal NRG-GI002	Title: <i>Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)</i> Presenter: Thomas J. George, MD Abstract #: 7	Session Time: 2:00 PM–3:30 PM Location: Level 3, Ballroom Session C: Cancers of the Colon, Rectum, and Anus Time: 2:42 PM-2:52 PM Oral Presentation
GI-Colorectal NRG-GI004	Title: <i>NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)</i> Presenter: Michael Overman, MD Abstract #: TPS258	Session Time: 9:30 AM–10:55 AM Location: Level 1, West Hall Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus Poster Presentation
GI-Colorectal NRG-GI005	Title: <i>Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA)</i> Presenter: Van K. Morris, MD Abstract #: TPS259	Session Time: 9:30 AM–10:55 AM Location: Level 1, West Hall Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus Poster Presentation
GI-Colorectal NRG-GI008	Title: <i>NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US)</i> Presenter: Christopher Lieu, MD Abstract #: TPS260	Session Time: 9:30 AM–10:55 AM Location: Level 1, West Hall Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus Poster Presentation
Disease Site & Study #	The following presentation includes NRG author/investigators from an NSABP Foundation study	Date/Time*/Location
GI-Colorectal NSABP C-14	Title: <i>NSABP C-14: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease</i> Presenter: Mohamed E. Salem, MD Abstract #: TPS284 NSABP Investigator: Mohamed E. Salem, MD	Session Date/Time: Saturday, January 21, 2023, 9:30-10:55 AM Location: Level 1, West Hall Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus Poster Presentation

* All times are EST